Current pharmacogenomic approaches to clinical drug development

Pharmacogenomics

Volumn 1, Issue 2, 2000, Pages 115-123

  Murphy, Michael P ^a,b  

^a PPGx Inc   (United States)

^b NONE   (United States)

Author keywords

Clinical trials; Drug metabolism; Drug metabolism enzymes; Pharmacogenetics; Pharmacogenomics; Polymorphisms; Single nucleotide polymorphisms (SNPs)

Indexed keywords

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; GENOTYPE; HUMAN; METHODOLOGY; PHARMACOGENETICS; REVIEW;

CLINICAL TRIALS; GENOTYPE; HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL;

EID: 0034189084     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.1.2.115     Document Type: Review

References (25)

1. NEBERT DW: Pharmacogenetics: 65 candles on the cake. Pharmacogenetics (1997) 7:435-440. Excellent historical perspective of pharmacogenetics.
2. EVANS WE, RELLING MV: Pharmacogenetics: translating functional genomics into rational therapeutics. Science (1999) 286:487-491. Excellent review article.
3. KLEYN PW, VESELL ES: Genetic variation as a guide to drug development. Science (1998) 281:1820-1821. Review of using a pharmacogenomic approach to drug development.
4. BHANDARIM, GARG R, GLASSMAN R, MA P: The pharmacogenomics challenge-the only option is how and when you participate. In Vivo (March 1999) 17:36-41. Excellent review of benefits and risks using pharmacogenomics during drug development.
5. COLLINS FS: Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics (1999) 54:41-47. Application of genetic testing to enhance medical practice including challenges and underlying concerns.
6. ZUHLSDORF MT: Relevance of pheno- and genotyping in clinical drug development. Int. J. Clin. Pharmacol. Ther. (1998) 36(11):607-612. Advantages and disadvantages of phenotyping and genotyping during drug development.
7. GRIESE EU, Zanger UM, Brudermanns U et al: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 8:15-26.
8. SACHSE C, BROCKMOLLER J, STEFFEN B, ROOTS I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. (1997) 60:284-295.
9. FUNCK-BRENTANO C, THOMAS G, JACQZ-AIGRAIN E et al.: Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainlde in humans. J. Pharmacol. Exp. Ther.(1992) 263:780-786.
10. MURPHY MP: PFGx client database. (1997-1999).
11. LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA (1998) 279:1200-1205.
12. KUHLMANN J: Responsibilities of clinical pharmacology in the early phase of drug development. Med. Klin. (1999) 94(5):290-299. Outlines the importance of using pharmacogenetics when assessing the clinical pharmacology of new drugs.
13. CHEN S, CHOU W-H, BLOUIN RA et al.: The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening cost and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther. (1996) 60:522-534. Documents the concordance between CYP2D6 genotyping and phenotyping. Excellent review of pharmacoeconomic justification for genotyping.
14. MURPHY MP, BEAMAN ME, CLARK LS et al.: Prospective genotyping as an exclusion crierion for enrollment of a Phase III clinical trial. Pharmacogenetics (accepted April 2000). Case study of prospective genotyping during Phase III clinical trials highlighting advantages in patient safety and efficiency of drug development.
15. BERTILSSON L, ABERG-WISTEDT A: The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br. J. Clin. Pharm. (1983)15:388-390.
16. BLUHM RE, WILKINSON GR, SHELTON R, BRANCH RA: Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin. Pharmacol. Ther. (1993) 53:89-95.
17. GILMAN AG, RALL TW, NIES AS, TAYLOR P: Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th Edition. McGraw-Hill, New York, USA (1993):411-413.
18. JACOBSEN H, HAENGGI M, OTT M et al.: Reduced sensitivity to saquinavir: an update on genotyping from Phase I/II trials. Antiviral Res. (1996) 29(1):95-97.
19. RACE E, GILBERT SM, SHELDON JG et al.: Correlation of response to treatment and HIV genotypic changes during Phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS (1998) 12(12):1465-1474.
20. DURANT J, CLEVENBERGH P, HALFON P et al.: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet (1999) 353:2195-2199.
21. MARTINEZ FD, GRAVES PE, BALDINI M, SOLOMON S, ERICKSON R: Association between genetic polymorphisms of the beta2-adrenoreceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. (1997) 100(12):3184-3188.
22. FARLOW MR: Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Neurology (1997) 48(Suppl. 6):S30-S34.
23. SMERALDI E, ZANARDI R, BENEDETTI F, DI BELLA D, PEREZ J, CATALANO M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiat. (1998) 3:508-511.
24. SHAK S: Case study: Genetech and the development of Herceptin. Second Annual Pharmacogenomics Event. European Centre for Pharmaceutical Information, London, England (2000).
25. ANDERSON WH, FITZGERALD CQ, MANASCO PK: Current and future applications of pharmacogenomics. New Horizons (1999) 7:262-269.